aim: To provide a balanced account of psilocybin treatment of depression for expectations to be appropriately set. method: Review and discussion of key psilocybin efficacy studies. Reporting of side effects and risk of harm with psychedelic treatments. Comparisons and contrasts with ketamine studies of treatment-resistant depression (TRD). result: Early psilocybin studies offer promise but...
Psychedelic-assisted therapies are gaining interest as an innovative treatment for problems with mental health and addictions, and there are several clinical trials in this area currently being conducted in Aotearoa New Zealand. However, many stakeholder groups hold concerns about cultural acceptability and safety. While psychedelic substances have a long history overseas in various Indigenous...
An increasing number of young patients with severe bladder overactivity syndrome potentially caused by recreational ketamine use has been treated in our department. Ketamine has become a popular and increasingly used recreational drug in New Zealand. Ketamine bladder syndrome has been reported internationally; however, local New Zealand data do not exist. It can lead to irreversible damage to...
The New Zealand Medical Journal (NZMJ) is the principal scientific journal for the medical profession in New Zealand. The Journal has become a fundamental resource for providing research and written pieces from the health and medical industry.